Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 2/20 | 0.58 |
| ▸ | ABL1 | P00519 | 1/20 | 0.58 |
| ▸ | RAF1 | P04049 | 1/20 | 0.58 |
| ▸ | LYN | P07948 | 1/20 | 0.58 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 13/20 | 0.58 |
| ▸ | TNF | P01375 | 3/20 | 0.58 |
| ▸ | MAPK12 | P53778 | 10/20 | 0.57 |
| ▸ | HCK | P08631 | 5/20 | 0.56 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.54 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.54 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4091363 | 0.89 | PTK2 (0.61) | SRCABL1RAF1LYNMAPK9 | |
| SCHEMBL7687888 | 0.87 | SRC (0.65) | SRCABL1RAF1LYNMAPK9 | |
| SCHEMBL4086637 | 0.87 | MAPK9 (0.56) | SRCABL1RAF1LYNMAPK9 | |
| SCHEMBL4095625 | 0.87 | SRC (0.56) | SRCABL1RAF1LYNMAPK9 | |
| SCHEMBL4092399 | 0.86 | ABL1 (0.62) | SRCABL1RAF1LYNMAPK9 | |
| SCHEMBL4094274 | 0.86 | MAPK14 (0.58) | SRCABL1RAF1LYNMAPK9 | |
| SCHEMBL4087767 | 0.86 | MAPK14 (0.57) | SRCABL1RAF1LYNMAPK9 | |
| SCHEMBL4085378 | 0.85 | SRC (0.54) | SRCABL1RAF1LYNMAPK9 | |
| SCHEMBL4258868 | 0.84 | MAPK14 (0.58) | SRCABL1RAF1LYNMAPK9 | |
| SCHEMBL4267189 | 0.83 | MAPK14 (0.57) | SRCABL1RAF1LYNMAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123516-A1 | Method of treating mucus hypersecretion | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2007-05-31 | — | — | US | claimed |
| EP-1690854-A1 | Heterocyclic urea and related compounds useful as anti-inflammatory agents | Boehringer Ingelheim Pharmaceuticals, Inc. (US) | 2006-08-16 | — | — | EP | claimed |
| EP-1658060-A2 | METHODS OF TREATING COPD AND PULMONARY HYPERTENSION | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-05-24 | — | — | EP | claimed |
| US-20050148555-A1 | Methods of treating COPD and pulmonary hypertension | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-07-07 | — | — | US | claimed |
| WO-2005018624-A2 | METHODS OF TREATING COPD AND PULMONARY HYPERTENSION | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-03-03 | — | — | WO | claimed |
| EP-1466906-A1 | Heterocyclic urea and related compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-10-13 | — | — | EP | claimed |
| US-20030220336-A1 | Method of treating mucus hypersecretion | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-11-27 | — | — | US | claimed |
| US-6358945-B1 | CYTOKINE, TUMOR NECROSIS FACTOR, AND INTERLEUKIN INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-03-19 | — | — | US | claimed |
| EP-2116245-A2 | EGFR kinase inhibitor combinations for treating respiratory and gastrointestinal disorders | Boehringer Ingelheim International GmbH (DE) | 2009-11-11 | — | — | EP | disclosed |
| US-20090017036-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | JUNG BIRGIT | 2009-01-15 | — | — | US | disclosed |
| US-7276491-B2 | Anticoagulant and fibrinolytic therapy using p38 MAP kinase inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| US-20070155724-A1 | Methods of Treating Cytokine Mediated Diseases | MOSS NEIL | 2007-07-05 | — | — | US | disclosed |
| US-20070123516-A1 | Method of treating mucus hypersecretion | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2007-05-31 | — | — | US | disclosed |
| EP-1784224-A2 | EGFR KINASE INHIBITOR COMBINATIONS FOR TREATING RESPIRATORY AND GASTROINTESTINAL DISORDERS | Boehringer Ingelheim International GmbH (DE) | 2007-05-16 | — | — | EP | disclosed |
| WO-2003022273-A1 | METHODS OF TREATING CYTOKINE MEDIATED DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-03-20 | — | — | WO | disclosed |
| US-20020082256-A1 | Compounds useful as anti-inflammatory agents | BETAGERI RAJASHEHAR (US) | 2002-06-27 | — | — | US | disclosed |
| US-20020055507-A1 | Compounds useful as anti-inflammatory agents | BETAGERI RAJASHEHAR (US) | 2002-05-09 | — | — | US | disclosed |
| US-6358945-B1 | CYTOKINE, TUMOR NECROSIS FACTOR, AND INTERLEUKIN INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-03-19 | — | — | US | disclosed |
| EP-1165516-A2 | HETEROCYCLIC UREA AND RELATED COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000055139-A2 | HETEROCYCLIC UREA AND RELATED COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155724-A1 | Methods of Treating Cytokine Mediated Diseases | TNF, IL2, IL1B | SRC 2244/4885ABL1 2843/4885RAF1 2509/4885 |
| US-20050148555-A1 | Methods of treating COPD and pulmonary hypertension | PTGIS, PTGS1, MAPKAPK5 | SRC 2475/4885ABL1 2764/4885RAF1 663/4885 |
| US-20090017036-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | BDKRB2, EDNRB, GRK5 | SRC 1016/4885ABL1 1152/4885RAF1 300/4885 |
| US-20020082256-A1 | Compounds useful as anti-inflammatory agents | NFKBIA, TNF, MPO | SRC 2715/4885ABL1 3659/4885RAF1 2736/4885 |
| US-20070123516-A1 | Method of treating mucus hypersecretion | MUC1, CFTR, MAPKAPK5 | SRC 1828/4885ABL1 719/4885RAF1 464/4885 |
| US-20020055507-A1 | Compounds useful as anti-inflammatory agents | NFKBIA, TNF, MPO | SRC 2715/4885ABL1 3659/4885RAF1 2736/4885 |
| US-20030220336-A1 | Method of treating mucus hypersecretion | MUC1, CFTR, MAPKAPK5 | SRC 1828/4885ABL1 719/4885RAF1 464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.